Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02051751
Title A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals

breast cancer

Advanced Solid Tumor

head and neck cancer


Alpelisib + Paclitaxel

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP

Facility Status City State Zip Country Details
Highlands Oncology Group Fayetteville Arkansas 72703 United States Details
Horizon Oncology Center BioAdvance Lafayette Indiana 47905 United States Details
Novartis Investigative Site Toulouse Cedex 9 31059 France Details
Novartis Investigative Site Milano MI 20141 Italy Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
*Shaded cells indicate that there was no data available from for the field